Search

We report the analysis of 1 year of data from the first cohort of 15 patients enrolled in an open-label, first-in-human, dose-escalation phase I study (ClinicalTrials.gov: NCT03282760, EudraCT2015-004855-37) to determine the feasibility, safety, and tolerability of the transplantation of allogeneic human neural stem/progenitor cells (hNSCs) for the treatment of secondary progressive multiple sclerosis. Participants were treated with hNSCs delivered via intracerebroventricular injection in combination with an immunosuppressive regimen. No treatment-related deaths nor serious adverse events (AEs) were observed. All participants displayed stability of clinical and laboratory outcomes, as well as lesion load and brain activity (MRI), compared with the study entry. Longitudinal metabolomics and lipidomics of biological fluids identified time- and dose-dependent responses with increased levels of acyl-carnitines and fatty acids in the cerebrospinal fluid (CSF). The absence of AEs and the stability of functional and structural outcomes are reassuring and represent a milestone for the safe translation of stem cells into regenerative medicines.

The main objective of this phase I trial was to assess the feasibility and safety of microtransplanting human neural stem cell (hNSC) lines into the spinal cord of patients with amyotrophic lateral sclerosis (ALS). Eighteen patients with a definite diagnosis of ALS received microinjections of hNSCs into the gray matter tracts of the lumbar or cervical spinal cord. Patients were monitored before and after transplantation by clinical, psychological, neuroradiological, and neurophysiological assessment. For up to 60 months after surgery, none of the patients manifested severe adverse effects or increased disease progression because of the treatment. Eleven patients died, and two underwent tracheotomy as a result of the natural history of the disease. We detected a transitory decrease in progression of ALS Functional Rating Scale Revised, starting within the first month after surgery and up to 4 months after transplantation. Our results show that transplantation of hNSC is a safe procedure that causes no major deleterious effects over the short or long term. This study is the first example of medical transplantation of a highly standardized cell drug product, which can be reproducibly and stably expanded ex vivo, comprising hNSC that are not immortalized, and are derived from the forebrain of the same two donors throughout this entire study as well as across future trials. Our experimental design provides benefits in terms of enhancing both intra- and interstudy reproducibility and homogeneity. Given the potential therapeutic effects of the hNSCs, our observations support undertaking future phase II clinical studies in which increased cell dosages are studied in larger cohorts of patients. Stem Cells Translational Medicine 2019

Background: We report the initial results from a phase I clinical trial for ALS. We transplanted GMP-grade, fetal human neural stem cells from natural in utero death (hNSCs) into the anterior horns of the spinal cord to test for the safety of both cells and neurosurgical procedures in these patients. The trial was approved by the Istituto Superiore di Sanità and the competent Ethics Committees and was monitored by an external Safety Board. Methods: Six non-ambulatory patients were treated. Three of them received 3 unilateral hNSCs microinjections into the lumbar cord tract, while the remaining ones received bilateral (n = 3 + 3) microinjections. None manifested severe adverse events related to the treatment, even though nearly 5 times more cells were injected in the patients receiving bilateral implants and a much milder immune-suppression regimen was used as compared to previous trials. Results: No increase of disease progression due to the treatment was observed for up to18 months after surgery. Rather, two patients showed a transitory improvement of the subscore ambulation on the ALS-FRS-R scale (from 1 to 2). A third patient showed improvement of the MRC score for tibialis anterior, which persisted for as long as 7 months. The latter and two additional patients refused PEG and invasive ventilation and died 8 months after surgery due to the progression of respiratory failure. The autopsies confirmed that this was related to the evolution of the disease. Conclusions: We describe a safe cell therapy approach that will allow for the treatment of larger pools of patients for later-phase ALS clinical trials, while warranting good reproducibility. These can now be carried out under more standardized conditions, based on a more homogenous repertoire of clinical grade hNSCs. The use of brain tissue from natural miscarriages eliminates the ethical concerns that may arise from the use of fetal material.

Background: We report the initial results from a phase I clinical trial for ALS. We transplanted GMP-grade, fetal human neural stem cells from natural in utero death (hNSCs) into the anterior horns of the spinal cord to test for the safety of both cells and neurosurgical procedures in these patients. The trial was approved by the Istituto Superiore di Sanità and the competent Ethics Committees and was monitored by an external Safety Board. Methods: Six non-ambulatory patients were treated. Three of them received 3 unilateral hNSCs microinjections into the lumbar cord tract, while the remaining ones received bilateral (n = 3 + 3) microinjections. None manifested severe adverse events related to the treatment, even though nearly 5 times more cells were injected in the patients receiving bilateral implants and a much milder immune-suppression regimen was used as compared to previous trials. Results: No increase of disease progression due to the treatment was observed for up to18 months after surgery. Rather, two patients showed a transitory improvement of the subscore ambulation on the ALS-FRS-R scale (from 1 to 2). A third patient showed improvement of the MRC score for tibialis anterior, which persisted for as long as 7 months. The latter and two additional patients refused PEG and invasive ventilation and died 8 months after surgery due to the progression of respiratory failure. The autopsies confirmed that this was related to the evolution of the disease. Conclusions: We describe a safe cell therapy approach that will allow for the treatment of larger pools of patients for later-phase ALS clinical trials, while warranting good reproducibility. These can now be carried out under more standardized conditions, based on a more homogenous repertoire of clinical grade hNSCs. The use of brain tissue from natural miscarriages eliminates the ethical concerns that may arise from the use of fetal material.

Recensione del film di Annaud

Recensione del film di Alessandro Siani

Recensione del film di Ficarra e Picone: Salvo e Valentino, due amici rimasti disoccupati, lasciano Palermo per trasferirsi al paesello d'origine, la cui popolazione è prevalentemente anziana. Una volta a Monteforte hanno un'idea geniale che ocnsentirà loro di guadagnare soldi senza lavorare...

Recensione del film di Ken Loach

Recensione del film di Volfango de Biasi

Recensione del film di Josh Boone

We discuss a variety of clustering problems arising in combinatorial applications and in classifying objects into homogenous groups. For each problem we discuss solution strategies that work well in practice. We also discuss the importance of careful modelling in clustering problems. © 1996 Kluwer Academic Publishers.

We discuss a variety of clustering problems arising in combinatorial applications and in classifying objects into homogenous groups. For each problem we discuss solution strategies that work well in practice. We also discuss the importance of careful modelling in clustering problems. © 1996 Kluwer Academic Publishers.

We discuss a variety of clustering problems arising in combinatorial applications and in classifying objects into homogenous groups. For each problem we discuss solution strategies that work well in practice. We also discuss the importance of careful modelling in clustering problems. © 1996 Kluwer Academic Publishers.

Metamorphic framework rocks of the southern Sierra Nevada occur primarily as N to NW striking, steeply dipping septa, within or separating granitoid plutons. The Lake Isabella area offers an excellent opportunity to study some of the interesting structural and stratigraphic problems posed by the southern Sierra framework rocks. Figure 1 is a generalized geologic map of the Lake Isabella region which focuses mainly on the metamorphic framework rocks. The map is derived primarily from our detailed mapping which was based on several earlier field studies. The general distribution of the major igneous and metamorphic units of the region was originally mapped by Miller and Webb (1940) with contributions by Jenkins (1961) and Alvarez (1962). Miller and Webb (1940) termed the distinctive quartz-rich metasedimentary rocks and marble of the region the Kernville series. Detailed mapping immediately adjacent to Lake Isabella by L.E. Weiss (unpublished data) revealed some of the complex deformation patterns in rocks of the Kernville Series, and also led to the discovery of the only fossil 1oca1ity of the region. In later regional studies Saleeby and others (1978) noted that the Kernville Series and newly discovered silicic metavolcanic rocks of the area were similar to the Kings sequence of the central Sierra as defined by Bateman and Clark (1974), Metamorphic framework rocks referred to as the Kings sequence by these workers consist of quartz-rich metasedimentary strata, marble, local pelite and scattered intervals of silicic metavolcanic rocks forming numerous steeply dipping septa in the central part of the range. Recognizing that regional workers are more familiar with Kings sequence rocks of the central Sierra, Saleeby and others (1978) suggested that Kernv111e Series rocks be termed Kings sequence, and that such rocks also extend southward from the Lake Isabella area to the southern terminus of the range, Thus the Kings sequence extends for ~300 km along the axis of the S